According to Dezhan Health Notice, the WYY026B injection clinical trial application submitted by the wholly-owned subsidiary Honghui was recently approved by the US FDA to carry out clinical research according to the submitted plan. The indication is acute ischemic stroke. The IND number is 178927.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.